IECM
CORT icon

Intrinsic Edge Capital Management’s Corcept Therapeutics CORT Stock Holding History

Intrinsic Edge Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,947
Closed -$4.8M – 120
2025
Q4 		$4.8M Buy
137,947
+26,000
+23% +$2.04M 0.86% 52
2025
Q3 		$9.3M Sell
111,947
-35,610
-24% -$2.58M 1.3% 29
2025
Q2 		$10.8M Buy
147,557
+25,000
+20% +$1.81M 1.52% 25
2025
Q1 		$14M Sell
122,557
-63,593
-34% -$3.87M 2.57% 14
2024
Q4 		$9.38M Hold
186,150
– – 1.14% 32
2024
Q3 		$8.62M Buy
186,150
+5,130
+3% +$182K 1.04% 35
2024
Q2 		$5.88M Buy
+181,020
New +$4.96M 0.53% 62
2024
Q1 		– Sell
-466,876
Closed -$15.2M – 155
2023
Q4 		$15.2M Buy
+466,876
New +$12.8M 1.52% 23

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Intrinsic Edge Capital Management's CORT Position: Q1 2026 in Review

Intrinsic Edge Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 137,947 shares — an estimated $4.8M sold.

Intrinsic Edge Capital Management first reported a position in CORT in Q4 2023 and held it in 8 quarters. The position peaked at $15.2M in Q4 2023. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Intrinsic Edge Capital Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 137,947 Corcept Therapeutics shares in Q1 2026, an estimated $4.8M.
  • Intrinsic Edge Capital Management first reported a position in Corcept Therapeutics in Q4 2023 and held it in 8 quarters.
  • Intrinsic Edge Capital Management's Corcept Therapeutics position peaked at $15.2M in Q4 2023.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Intrinsic Edge Capital Management's 13F filing for Q1 2026, filed 18 May 2026.